The conclusion you can draw from analyzing the studies is that there is no consistent improvement in relapse-free or overall survival with high-dose interferon. I would categorize high-dose interferon as an unreasonable adjuvant therapy.
Dr. Kelly M. McMasters is professor and chairman of the department of surgery at the University of Louisville (Ky.) School of Medicine. He disclosed that he has received grant funding and honoraria from Schering. He is also a board member for Provectus, is a member of its scientific advisory board, and receives consulting fees from the company.